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Abstract 
MTA1(a metastasis-associated gene) is a newly discovered human gene (residing on chromsome 14q32.3) that belongs 
to a family of cancer progression-related genes (MTA). The mRNA product of MTA1along with its protein product 
MTA1 have been reported to be over-expressed in a wide variety of animal and human tumors. For example, th  
expression of MTA1 and its encoded protein MTA1 correlates with the malignant properties of many human cancers, 
including cancers of the breast, colon, stomach, liver, prostate and others. The MTA proteins have been shown to be 
ubiquitinated transcriptional co-repressors that function in histone deacetylation and are part of the NuRD complex, a 
nucleosome remodeling and histone deacetylating complex whose stability appears to be regulated by ubiquitinated 
MTA1 binding to E3 ubiquitin ligase constitutive photomorphogenesis protein-1 (COP1). The MTA1 protein plays an 
essential role in c-MYC-mediated cell transformation, and its expression correlates with mammary gland tumor 
formation. In the latter, MTA1 helps convert mammary cells to more aggressive phenotypes by repression of the 
estrogen receptor (ER) via trans-activation through deacetylation of chromatin in the ER-responsive element of ER-
responsive genes. Another member of the MTA family, MTA3, is induced by estrogen and represses the expression of 
the transcriptional repressor Snail, a master regulator of epithelial to mesenchymal transformation, resulting in the 
expression of the cell adhesion molecule E-cadherinand maintenance of a differentiated, normal epithelial phenotype in 
mammary cells. An important activity mediated by both MTA1 and MTA2 is deacylation and inactivation of tumor 
suppressor p53protein, in part by controlling its stability by inhibiting ubiquitination, leading to inhibition of growth 
arrest and apoptosis. Another factor deacetylated and stabilized by MTA1 NuRD complex is hypoxia-inducible factor-
1α (HIF-1α), which is involved in angiogenesis. Therefore, the MTA proteins represent a possible set of master co-
regulatory molecules involved in the carcinogenesis and progression of various malignant tumors. As such, they could 
be important new tools for cancer diagnosis and treatm nt. 
 
1. Introduction - The MTA gene 
family 
An important advance in cancer research has been the 
discovery of a wide variety of new molecules involved 
in carcinogenesis and cancer progression. Although 
additional cancer-related molecules will be identified in 
the future, these molecules must fulfill two major 
requirements in order to be clinically useful as 
molecular targets useful for the diagnosis and treatm nt 
of human cancers (Toh and Nicolson, 2009).  
The first is that abnormalities must occur in the 
expression or structure of the molecules of interes, and 
their clinical relevance must be definitely demonstrated 
in independent studies on human cancers. The second 
is that the underlying molecular mechanisms necessary 
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for the molecules to exert their functions in 
carcinogenesis or cancer progression must be 
determined and confirmed in animal tumor models and 
clinical specimens. 
There have been a number of cancer-related genes and 
molecules that have been discovered in the last few 
years. In our laboratory we identified a candidate 
metastasis-associated gene by the use of a differential 
cDNA screening method. Using this approach we 
identified a gene that was differentially over-expressed 
in highly metastatic rat mammary adenocarcinoma cell 
lines compared to poorly metastatic lines (Toh et al., 
1994; Toh et al., 1995). When this gene was sequenced, 
it was shown to be a completely new, novel gene 
without any homologous or related genes in the 
database at the time. This gene was named ta1 
(metastasis-associated gene-1). A homologous gene 
was also expressed in human cancer cell lines, and its 
human cDNA counterpart, MTA1, was subsequently 
cloned (Nawa et al., 2000) and found to reside on 
chromosome 14q32.3 (Cui et al., 2001). 
Using surgically removed human tissues we showed 
that high levels of MTA1mRNA expression were 
correlated to the invasive and growth properties of 
gastrointestinal cancers, including esophageal, gastric 
and colorectal cancers (Toh et al., 1997; Toh et al., 
1999). After these studies, several reports from other 
groups found similar correlations between MTA1 
expression and the malignant potentials of human 
cancers (reviewed in Toh and Nicolson, 2009). 
In addition to MTA1, other genes related to MTA1 have 
now been identified. This gene family, which we 
termed the MTAfamily, now has several members plus 
some splice variants (Toh and Nicolson, 2003; 
Manavathi and Kumar, 2007; Toh and Nicolson, 2009). 
Furthermore, studies on the molecular biological and 
biochemical properties of the MTA family have shown 
that the gene products of the main members of the 
family (proteins MTA1, MTA2 and MTA3) are tightly 
associated in a protein complex called NuRD 
(nucleosome remodeling and histone deacetylation), 
which has transcriptional regulatory functions via 
histone deacetylation and chromatin remodeling (Toh 
et al., 2000; Bowen et al., 2004). Interestingly, histone 
deacetylase activities correlate with squamous cell
carcinoma invasion (Toh et al., 2003). At the moment, 
the MTA family has attracted widespread attention as 
one of several key molecules that play indispensable 
roles in the pathogenesis and progression of a wide 
variety of cancers (Toh and Nicolson, 2003; Kumar et 
al., 2003; Manavathi et al., 2007b; Toh and Nicolson, 
2009). We will examine the significance of the 
expression of MTA family members in human cancers 
and the important molecular mechanisms that are 
currently known by which MTA proteins exert their 
cellular actions as well as discuss the potential cl nical 
applications of this protein family for the diagnosis and 
treatment of human cancers. 
2. The MTA family of proteins, their 
structures and cell location 
The MTA proteins represent a family of gene products 
encoded by three distinct genes (MTA1, MTA2 and 
MTA3), and six reported isoforms (MTA1, MTA1s, 
MTA1-ZG29p, MTA2, MTA3, and MTA3L). The 
molecular masses of the gene products of MTA1, 
MTA2 and MTA3 are approximately 80 kDa, 70 kDa 
and 65 kDa, respectively (Manavathi and Kumar, 2007; 
Toh and Nicolson, 2009). The nucleotide and protein 
alignment homologies and the phylogenetic 
comparative analyses have been discussed previously 
(Bowen et al., 2004; Manavathi and Kumar, 2007; Toh
and Nicolson, 2009). 
The MTA gene family sequences, with the exception of 
ZG-29p, contain several common domain structures 
(Singh and Kumar, 2007; Toh and Nicolson, 2009). 
One of these, the BAH (bromo-adjacent homology) 
domain is involved in protein-protein interactions. 
Another, the SANT (SWI, ADA2, N-CoR, TFIIIB-B) 
domain shares a high degree of homology with the 
DNA-binding domain of the Myb-related proteins, 
suggesting that this domain may be involved in DNA-
binding. The ELM (egl-27 and MTA1 homology) 
domain has an unknown function but could be involved 
in embryonic patterning (Solari et al., 1999). 
The MTA family members contain a highly conserved 
GATA-type zinc finger motif, suggesting direct 
interactions with DNA (Nawa et al., 2000). The MTA1 
protein has two src-homology (SH)-binding motifs at 
its C-terminal end-such binding domains are known to 
be important in signal transduction involving kinase, 
adaptor and scaffolding proteins (Toh et al., 1994; Toh 
et al., 1995; Singh and Kumar, 2007). Similarly, SH2- 
and SH3-binding domains are also found in MTA2 and 
MTA3 protein sequences (Toh et al., 1994; Toh et al., 
1995; Singh and Kumar, 2007). These common domain 
structures demonstrate that the MTA family is involved 
in protein-protein and protein-DNA interactions, 
indicating the anticipated roles of the MTA family of
proteins in signal transduction and transcriptional 
regulation (Toh and Nicolson, 2003; Singh and Kumar, 
2007; Toh and Nicolson, 2009). 
In addition to protein-protein and protein-DNA 
binding, MTA proteins contain basic nuclear 
localization signals (Toh et al., 1994; Toh et al.,1995; 
Singh and Kumar, 2007). They also localize in the 
nucleus in many human cancer cells (Toh et al.,1997; 
Toh et al., 1999); however, MTA1 localizes to both the
cytoplasm and nucleus in some tumors (Moon et al., 
2004; Balasenthil et al., 2006; Bagheri-Yarmand et al., 
2007). MTA3 also localizes to the nucleus, but without 
any apparent nuclear localization signal (Fujita et al., 
2003). A short splice-variant of MTA1, called MTA1s, 
is predominantly localized in the cytoplasm (Kumar et 
al., 2002). 
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3. MTA protein expression in 
various cancers and its possible 
clinical relevance 
Since the report by Toh et al. (1997) that the over-
expression of MTA1was significantly correlated to the 
malignant properties of human gastric and colorectal 
cancers, there have been several reports on the 
expression levels of MTA family members, especially 
of MTA1, in various human cancers (reviewed in Toh 
and Nicolson, 2009). These studies revealed that the 
expression levels of MTA family members correlate 
with pathogenic significance and prognosis (Toh and
Nicolson, 2009). The biological relevance of MTA 
proteins to carcinogenesis and cancer progression has 
been investigated in a few cancer models, such as 
breast and gastrointestinal cancers, and these will be 
discussed in more detail below. 
3.1 MTA1 protein and breast cancer 
MTA1 protein was originally identified as a candidate 
cancer progression molecule that was associated with 
breast cancer metastasis (Toh et al., 1994; Toh et al., 
1995). Subsequently, using antisense RNA of MTA1 a 
role for MTA1 in the growth properties of metastatic 
breast cancer cells was investigated. Using 
MTA1antisense RNA we found that the growth rates of 
highly metastatic breast cancer cell lines were inhibited 
significantly in a dose-dependent manner (Nawa et al., 
2000). More direct evidence to demonstrate an 
association of MTA1 expression levels with breast 
cancer malignant properties was obtained by 
Mazumdar et al. (2001). They demonstrated that forced 
expression of the MTA1 protein in the human breast 
cancer cell line MCF-7 was accompanied by an 
enhancement in the ability of MCF-7 cells to invade an 
artificial matrix and ability to grow in an anchorage-
independent manner. They also showed that the 
enhancement was associated with the interaction 
between MTA1 protein and histone deacetylase, 
resulting in a repression of estrogen receptor (ER) 
mediated transcription (Mazumdar et al., 2001). 
Using an animal model the Mazumdar et al. (2001) 
study was extended by further experiments 
demonstrating a direct in vivo effect of MTA1 on the 
carcinogenesis of breast cancer cells (Bagheri-Yarmand 
et al., 2004; Singh and Kumar, 2007). This group 
established a transgenic mice system that over-
expressed the MTA1 protein, and these MTA1-
transgenic mice revealed inappropriate development of 
their mammary glands. The MTA1-transgenic mice 
eventually developed hyperplastic nodules and 
mammary tumors, including mammary 
adenocarcinomas and lymphomas. 
The involvement of MTA1 in the carcinogenesis and 
progression of breast cancers was also shown by Martin 
et al. (2001; 2006). First, they mapped the 
chromosomal locus in 14q that might be responsible for 
axillary lymph node metastases in human breast 
cancers by comparing the rate of loss of heterozygosity 
between node-positive and node-negative breast 
cancers. The MTA1 gene was found to be contained in 
the same gene locus, suggesting that MTA1is a 
candidate for a breast cancer metastasis-promoting 
gene. Next, using immunohistochemistry they 
examined MTA1 protein expression in primary human 
breast cancer samples and demonstrated that node-
negative breast cancers with over-expression of MTA1 
protein had a higher risk of disease relapse similar to 
node-positive tumors. Therefore, the over-expression of 
MTA1 was proposed as a potential predictor of early 
disease relapse independent of node status (Martin et 
al,. 2006). 
Using surgically resected human breast cancer 
specimens Jang et al. (2006) showed that MTA1 over-
expression was closely associated with higher tumor 
grade and high intratumoral microvessel density. This 
suggested that MTA1 could be a useful predictor of an 
aggressive phenotype, and the MTA1 molecule could 
be considered as a possible angiogenesis-promoting 
molecule in breast cancers (Jang et al., 2006). 
3.2 MTA1 protein and gastrointestinal cancers 
MTA1 over-expression has been shown to be 
pathogenically significant in human gastrointestinal 
cancers. Using a reverse-transcription polymerase chain 
reaction (RT-PCR) method on surgically resected 
human gastric and colorectal cancer specimens were 
compared to paired normal counterpart tissues, and we 
found that the higher expression of MTA1 mRNA was 
significantly correlated to the depth of cancer invasion 
and extent of lymph node metastasis (Toh et al., 1997). 
This study was the first to demonstrate the clinical 
relevance of MTA1 expression to the malignant 
potentials of human cancers. Over-expression of MTA1 
mRNA was also shown in colorectal cancers compared 
to the normal counterpart tissues (Giannini et al.,
2005). 
Esophageal cancers have also been investigated for 
MTA1/MTA1 over-expression. Using a RT-PCR 
method we found that human esophageal squamous cell 
cancers over-express MTA1mRNA (Toh et al., 1999). 
The over-expressing cancer cells showed significantly 
higher frequencies of adventitial invasion and lymph 
node metastasis and tended to have higher rates of 
lymphatic involvement (Toh et al., 1999). Using 
immunohistochemistry we further examined the 
expression levels of MTA1 protein in human 
esophageal squamous cell cancers and reconfirmed the 
results obtained by RT-PCR (Toh et al., 2004). In the 
same study we also demonstrated that MTA1 protein 
was a predictor of poor prognosis after surgery (Toh et 
al., 2004). 
The roles of MTA1/MTA1 in small intestinal cancers 
have also been evaluated. Kidd et al. (2006a; 2007) and 
Modlin et al. (2006b) showed that it was useful to 
examine the expression of MTA1mRNA and MTA1 
protein in order to determine the malignant potential 
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and the propensity to metastasize of enterochromaffin 
cell cancers (small intestinal carcinoid tumors). When 
compared to nonmetastatic primary tumors, the 
expression of MTA1 was increased in malignant, 
invasive small intestinal carcinoid tumors and in 
metastases to liver and lymph nodes. In these cells loss 
of TGFβ expression modified expression, including 
increased MTA1 expression, of the genes involved in 
malignant behavior (Kidd et al., 2007). It was further 
reported that MTA1was a good candidate genetic 
molecular marker to discriminate between gastric 
carcinoids and other gastric neoplasms (Kidd et al., 
2006b) as well as malignant appendiceal carcinoids 
from benign tissue (Modlin et al., 2006a). In these 
studies, MTA1 and MTA1 expression were thought to 
be good markers of the malignant potential of carcinoid 
tumors. 
Other gastrointestinal-linked cancers, such as a 
pancreatic cancers and hepatocellular carcinomas, have
also been examined for the involvement of 
MTA1/MTA1 over-expression in carcinogenesis and 
cancer progression. Iguchi et al. (2000) examined 
MTA1 mRNA expression in pancreatic cancer cell lines 
and resected pancreatic cancer tissues and found that 
increased levels of MTA1 mRNA expression in the 
more progressed pancreatic cancers. Direct evidence o  
the role of MTA1/MTA1 in the progression of 
pancreatic cancer was provided by Hofer et al. (2004). 
Using a pancreatic cell line (PANC-1) they transfected 
MTA1cDNA into the cells and found that enhanced 
expression of MTA1 promoted the acquisition of an 
invasive and metastatic phenotype and enhanced the 
malignant potentials of the transformed cells 
(pancreatic adenocarcinomas) by modulation of the 
cytoskeleton via IQGAP1. In addition, Miyake et al.
(2008) showed the expression level of the MTA1 
protein correlated with poorer prognosis of pancreatic 
cancer patients. 
An association between MTA1/MTA1 expression and 
the malignant properties of hepatocellular carcinomas 
(HCC) was first reported by Hamatsu et al. (2003). In 
this study, MTA1 mRNA level was assessed by RT-
PCR in resected human HCC tissues, and its high 
expression predicted a lower disease-free survival rate 
after curative HCC hepatectomy. Using 
immunohistochemistry Moon et al. (2004) examined 
MTA1 protein expression in resected human HCC 
specimens and found that over-expression of MTA1 
was associated with HCC growth and vascular invasion 
and that nuclear localization of ERa inversely 
correlated with MTA1 expression. This suggested that
MTA1 was involved in negative regulatory 
mechanisms. 
Recently, Yoo et al. (2008) demonstrated that hepatitis 
B virus (HBV) X (HBx) protein strongly induced the 
expression of MTA1 and histone deacetylase 1 
(HDAC1). This suggests that positive crosstalk 
between HBx and MTA1/HDAC1 complex may occur,  
and this could be important in stabilizing hypoxia-
inducible factor-1α (HIF1-1α), which appears to play a 
critical role in angiogenesis and metastasis of HBV-
associated HCC (Yoo et al., 2008). Interestingly, it was 
reported that MTA1 was closely associated with 
microvascular invasion, frequent postoperative 
recurrence, and poor prognosis in patients with HCC, 
especially in those with HBV-associated HCC (Ryu et 
al., 2008). 
3.3 MTA1 protein and other cancers 
The reports on MTA1/MTA1 over-expression in human 
cancers have been reinforced by the experimental over-
expression or under-expression of MTA1 in human 
cells. For example, Mahoney et al. (2002) transfected 
MTA1 cDNA into immortalized human keratinocytes 
and demonstrated that forced over-expression of 
MTA1contributed to some metastatic cell properties, 
such as increased cell migration, invasion and survival 
in an anchorage independent medium. Nawa et al. 
(2000) used antisense MTA1 to suppress MTA1 levels 
and inhibit the growth of breast cancer cells in vitro. 
These authors subsequently showed that in vitro 
invasion of human MBA-MB-231 cells could be 
inhibited by antisense MTA1 (Nicolson et al., 2003). 
Similarly, using a human esophageal squamous cell 
carcinoma cell line, Qian et al. (2005) inhibited MTA1 
expression by RNA interference and found significant 
inhibition of the cells' in vitro invasion and migration 
properties. 
Possible relationships between MTA1/MTA1 
expression and malignant cell properties, such as 
invasion and metastasis, have been investigated in other
carcinoma and sarcoma systems. Using human non-
small cell lung cancer cells high expression of MTA1 
mRNA was correlated with lymph node metastasis 
(Sasaki et al., 2002). This has also been found to be the 
case in human ovarian cancers (Yi et al., 2003). 
Additionally, in thymomas advanced stage and 
invasiveness was related to MTA1 expression (Sasaki et 
al., 2001). 
Using various techniques the relationship between 
MTA1 expression and malignancy has been 
investigated in various cancers. For example, a 
potential role for MTA1 protein over-expression in the 
progression of human endometrial carcinomashas been
found by Balasenthil et al. (2006). Whereas in prostate 
cancers Hofer et al. (2004) showed that metastatic 
prostate tumors had significantly higher levels of 
MTA1 protein expression and higher percentages of 
tissue cores staining positive for MTA1 protein over-
expression than in clinically localized prostate cancers 
or benign prostate lesions. Most interestingly, using 
transgenic mice Kumar's group showed that MTA1 
over-expression was accompanied by a high incidence 
of spontaneous B cell lymphomas, including diffuse 
large B cell lymphomas (Bagheri-Yarmand et al., 2007; 
Balasenthil et al., 2007). The high expression of MTA1  
MTA1 of the MTA (metastasis-associated) gene family and its encoded proteins:  Toh Y, Nicolson GL 





Atlas Genet Cytogenet Oncol Haematol. 2011; 15(3)  307 
in human diffuse B-cell lymphomashas been reported 
(Hofer et al., 2006). In the transgene model, mammary 
adenocarcinomas also developed (Bagheri-Yarmand et 
al., 2004). 
Microarrays have also been used to follow MTA1and 
other genes' expression. Using DNA microarray 
analysis Roepman et al. (2006) investigated gene 
expression patterns in lymph node metastases of head
and neck squamous cell carcinomas. They found that 
the MTA1 gene was the only single gene that showed 
consistent over-expression between large numbers of 
matched paired samples of primary tumor and lymph 
node metastases. 
4. Biological significance of the 
MTA proteins 
It has been demonstrated by different laboratories (s e 
Section 3) that MTA1/MTA1 over-expression is closely 
correlated with cancer progression (and in some cass 
with carcinogenesis) in a wide range of different 
cancers. This strongly indicates that the MTA1 protein 
may be an important functional molecule in 
malignancy. Thus, it is necessary to clarify the 
molecular mechanisms by which the MTA protein 
family members exert their functions. 
Only then can MTA proteins be utilized for diagnosis 
or treatment of human cancers. There are several 
important cellular functions of MTA proteins that have 
been recently clarified, such as those that are related to 
carcinogenesis and cancer progression. 
4.1 MTA proteins and the nucleosome remodeling-
histone deacetylation (NuRD) complex and 
transcriptional regulation 
The molecular and biochemical functions of the MTA1 
protein were first investigated by four independent 
groups. In these studies, two different chromatin-
modifying activities, ATP-dependent nucleosome 
remodeling activity and histone deacetylation, were 
functionally and physically linked in the same protein 
complex. This complex has been named the NuRD 
(Nucleosome Remodeling and Histone Deacetylation). 
The NuRD complex contains HDAC1, HDAC2, the 
histone binding proteins RbAp46/48 and the 
dermatomyositis-specific autoantigen Mi-2, which has 
been shown to have transcription repressing activity 
(Tong et al., 1998; Xue et al., 1998; Wade et al., 1999; 
Zhang et al., 1999; Bowen et al., 2004). 
The MTA1 protein was found in the NuRD complex by 
Xue et al. (1998), and this complex also possessed 
strong transcription repressing activity. Subsequently, 
Zhang et al. (1999) reported that a protein similar to 
MTA1 (named the MTA2 protein) was also a 
component of the NuRD complex, and they found that 
MTA2 protein was highly expressed in rapidly dividing 
cells. Later, MTA3 protein was identified as an 
estrogen-inducible gene product that is present in a 
distinct NuRD complex (Fujita et al., 2003). We also 
reported the physical interaction between MTA1 
protein and HDAC1 (Toh et al., 2000). 
 
Figure 1. MTA proteins in a chromatin remodeling and histone deacetylation complex (NuRD). This complex has transcription repression 
properties. The NuRD complex also contains histone deacetylases (HDAC1 and 2), major DNA binding protein 3 (MDB3), histone binding 
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The basic functions of the MTA protein family 
members appear to be exerted through NuRD 
complexes as chromatin remodeling and histone 
deacetylating activities (Figure 1). Although there are 
also non-histone deacetylating proteins in NuRD 
complexes, MTA proteins appear to be among the 
principal components (Figure 1). In addition, the MTA-
NuRD complexes show transcriptional repression 
activities (Feron, 2003; Kumar et al., 2003; Manavathi 
et al., 2007b; Singh and Kumar, 2007). Although all 
MTA protein family members are found in NuRD 
complexes, each MTA protein may form a distinct 
NuRD complex that targets different sets of promoters 
(Bowen et al., 2004). 
4.2 MTA protein repression of the trans-activating 
activity of estrogen receptor-alpha 
The involvement of MTA proteins in NuRD complexes 
suggested that such complexes might function in 
chromatin remodeling and histone deacetylation, but a 
direct target of a MTA protein had to first be identified 
(Mazumdar et al., 2001). MTA1 protein was identified 
as a molecule induced by heregulin-beta1 (HRG), a 
growth factor that is a natural ligand of the human 
epidermal growth factor receptors HER3 and HER4. It 
can also trans-activate HER2 (c-erbB-2) in human 
breast cancer cell lines. Mazumdar et al. (2001) showed 
that MTA1 protein directly interacted with the ligand-
binding domain of the estrogen receptor ERα and that 
HRG stimulated the association of MTA1 and HDAC2 
on the chromatin site of an ER-responsive 
element (ERE) in the promoter regions of estrogen 
responsive genes, such as pS2 and c-myc. This could 
explain the activation of the HRG/HER2 pathway in 
ER-positive breast cancers and the suppression of ERα 
functions, which could result in the more invasive and 
aggressive phenotypes observed in ER-negative breast 
cancers (Cui et al., 2006). 
The repressive function of MTA1 protein on ERα is 
mediated via histone deacetylation by HDAC1 and 
HDAC2, suggesting that MTA1 protien has a potent 
co-repressor function during the trans-activation of 
ERα through histone deacetylation (Figures 2 and 3). 
MTA2 protein has also been shown to physically 
interact with ERα and to repress its trans-activating 
function. This could explain the over-expression of 
MTA2 protein in cells that were unresponsive to 
estrogen as well as suppression of estrogen-induced 
colony formation in breast cancer cells (Cui et al., 
2006). 
MTA proteins also have other activities. For example, 
Khaleque et al. (2008) showed that MTA1 protien 
binds to a heat shock factor 1 (HSF1), the 
transcriptional activator of the heat shock genes, in 
vitro and in human breast carcinoma samples. They 
demonstrated that HSF1-MTA1 complex formation 
was strongly induced by HRG and that the complex 
was incorporated into a NuRD complex that 
participated in the repression of estrogen-dependent 
transcription in breast cancer cells treated with HRG 
(Khaleque et al., 2008). 
 
 Figure 2. A possible role for MTA proteins in carcinogenesis and cancer progression. In this scheme the main functions of the MTA 
family of proteins are presented. (A) MTA1 protein is included in a NuRD complex that represses the transactivation function of estrogen 
receptor (ER), rendering breast cancer cells more phenotypically aggressive. MTA1 proteins in NuRD complexes are proposed to be one 
of the first downstream targets of c-MYC function, and it is essential for the transformation potential of c-MYC. MTA1s is a splice-variant 
of MTA1 that localizes in the cytoplasm where it sequesters ERα, preventing the ligand-induced nuclear translocation of Erα, thus 
stimulating the development of the malignant phenotype of breast cancer cells. (B) MTA3 protein induced by estrogen represses the 
expression of the transcriptional repressor Snail, a master regulator of epithelial to mesenchymal transitions, resulting in the expression 
of the cell adhesion molecule E-cadherin and maintenance of a differentiated, normal epithelial status in breast cells (from Toh and 
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There are apparently several molecules, such as 
ménage-à-trois 1 (MAT1), MTA1-interacting co-
activator (MICoA) and nuclear receptor interacting 
factor 3 (NRIF3), that can interact with MTA1 protein 
and repress the trans-activation function of ERα 
(Manavathi et al., 2007b). These three MTA1-binding 
proteins themselves have co-activator properties upon 
ERα trans-activation. MAT1, an assembly and 
targeting ring finger factor for cyclin-dependent kinase-
activating kinase (CAK), has been identified by 
Talukder et al. (2003) as a MTA1-binding protein. The 
interactions between CAK and MTA1 protein 
apparently regulate the trans-activation activity of ERα 
in a CAK-dependent manner in breast cancer cells. In 
contrast, MICoA-mediated ERα trans-activation 
functions are opposed by MTA1 protein through the 
recruitment of HDACs (Mishra et al., 2003). In 
addition, the interactions between MTA1 protein and 
NRIF3 (an estrogen-inducible gene) may be important 
in modulating the sensitivity of breast cancer cells to 
estrogen (Talukder et al., 2004). 
Another MTA1-binding protein partner, Lim-only 
protein 4 (LMO4), has been identified by Singh et al. 
(2005). LMO4 was found to be a component of the 
MTA1 co-repressor complex, and its over-expression 
repressed ERα trans-activation in a HDAC-dependent 
manner. This has been proposed to result in the 
acquisition of an ERα-negative phenotype with its 
known increased aggressiveness in breast cancer cells 
(Singh et al., 2005). 
Variants of MTA1 protein have also been found. For 
example, a truncated form of MTA1 protein has been 
identified and named MTA1s (Balasenthil et al., 2006). 
MTA1s is a splice-variant of MTA1, and it contains an
ER-binding motif (nuclear binding motif) without any 
nuclear localization signals at its C-terminus. This 
truncated MTA protein localizes in the cytoplasm 
where it sequesters ERα, resulting in the blockage of 
ERα ligand-induced nuclear translocation and 
stimulation of acquisition of the malignant phenotype 
of breast cancer cells. This suggests that the regulation 
of the cellular localization of ERα by MTA1s protein 
may represent a mechanism for redirecting nuclear 
receptor signaling by nuclear exclusion. MTA1s 
protein has also been shown to associate with casein 
kinase I-gamma2, which is an estrogen-responsive 
kinase (Mishra et al., 2004). 
MTA3 protein is the newest addition to the MTA 
family. It was identified as an estrogen-dependent 
component of the Mi-2/NuRD transcriptional co-
repressor complex in breast epithelial cells (Fujita e  
al., 2003).  
The absence of MTA3 protein as well as the absence of 
ER results in an aberrantly increased expression of the 
transcriptional repressor Snail, a master regulator of 
epithelial-to-mesenchymal transition (EMT). This 
increased expression of Snail results in reduction in 
expression of the cell adhesion molecule E-cadherin, 
which subsequently modifies epithelial cell architecture 
and enhances invasive growth. MTA3 protein is a 
transcriptional target of ERα, and in the presence of 
estrogen ERα directly binds to the MTA3 promoter at 
the SP1 site in close proximity to the ERE half-site, 
resulting in stimulation of MTA3 transcription (Fujita et 
al., 2004; Mishra et al., 2004). Thus, MTA3 protein 
may function to maintain a well-differentiated, normal 
epithelial phenotype in breast cells. This is in stark 
contrast to MTA1 or MTA1s protein, where up-
regulation of MTA1 or MTA1s protein in breast cancer 
cells may repress MTA3 expression through repression 
of the ERα function, resulting in up-regulation of Snail, 
down-regulation of E-cadherin, promotion of an EMT 
phenotype and potentially an increase in metastatic 
potential. 
Forced expression of MTA3 protein inhibits ductal 
branching in virgin and pregnant mammary glands in 
MTA3-transgenic mice (Zhang et al., 2006). This 
property is in marked contrast to MTA1-transgenic 
mice, where there is inappropriate development of 
mammary glands, resulting in the development of 
hyperplastic nodules and mammary tumors, including 
adenocarcinomas and lymphomas (Bagheri-Yarmand et 
al., 2004; Manavathi and Kumar, 2007). MTA3 protein 
also represses Wnt4 transcription and secretion by 
inhibiting Wnt-target genes in mammary epithelial 
cells. This repression of Wnt4 transcription was found 
to be mediated through a MTA3-NuRD complex, 
which interacts with the Wnt4-containing chromatin in 
an HDAC-dependent process (Zhang et al., 2006). 
The fundamental actions of the MTA proteins are 
exerted via transcriptional repression by histone 
deacetylation; however, a transcriptional activating 
function has also been described for MTA complexes. 
Gururaj et al. (2006a, 2006b) showed that breast cancer 
amplified sequence 3 (BCAS3), a gene amplified and 
over-expressed in breast cancers, was a chromatin 
target of MTA1 protein, and the transcription of 
BCAS3 was stimulated by MTA1 protein. This 
suggested that MTA1 protein has a transcriptional co-
activator function in addition to its co-repressor 
function. A similar property has been also been 
suggested for mouse Mta2 protein (Matsusue et al., 
2001). 
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Figure 3. Deacetylation of non-histone proteins by MTA protein family complexes. (A) Tumor suppressor p53 protein is deacetylated and 
inactivated by both MTA1 and MTA2 proteins in NuRD complexes, resulting in inhibition of growth arrest and apoptosis. (B) 
Hypoxiainducible factor-1α (HIF-1α) is also deacetylated and stabilized by MTA1 protein, leading to angiogenesis (from Toh and 
Nicolson, 2009 with permission). 
 
4.3 MTA-NuRD protein complexes and 
deacetylation of non-histone proteins 
Chromatin histones and non-histone proteins are the 
protein targets for deacetylation by HDAC via NuRD 
complexes containing MTA proteins. The tumor 
suppressor gene p53 protein was the first non-histone 
protein that was reported to be deacetylated by MTA 
protein-containing NuRD complexes. Luo et al. (2000) 
reported that the deacetylation of p53 was mediated by 
an HDAC1 complex containing MTA2 protein. A 
MTA2-associated NuRD complex was involved, and 
this HDAC1/MTA2 complex interacted with p53 in 
vitro and in vivo and reduced significantly the steady-
state levels of acetylated p53. Deacetylation of p53 
causes an increase in its own degradation through 
MDM2 and a reduction in p53-dependent 
transcriptional activation. Eventually this results the 
repression of the normal p53 function that mediates cell 
growth arrest and apoptosis (Figure 3). The same 
phenomenon was observed between p53 and MTA1 
complexes. HDAC1/MTA1 complexes possessed 
deacetylation activity against p53 protein in human 
non-small cell carcinoma and human hepatoma cells, 
and the complexes were found to inhibit p53-induced 
apoptosis by attenuating the trans-activation functio  of 
p53 (Moon et al., 2007). More recently the stability of 
p53 was determined to be affected by MTA1 inhibiting 
p53 ubiquitination by E3 ubiquitin ligases double 
minute 2 (Mdm2) and constitutive photomorphogenic 
protein 1 (COP1). MTA1 competes with COP1 to bind 
to p53 and/or destabilize COP1 and Mdm2 (Li et al., 
2009b). MTA1 stability and degradation itself is 
controlled by ubiquitination, and degradation of MTA1 
is promoted by COP1-mediated hydrolysis (Li et al.,
2009b). 
HIF-1α (hypoxia-inducible factor-1α) is another 
important non-histone protein that is deacetylated by 
HDAC1/MTA1 complexes (Figure 3). HIF-1α is a key 
regulator of angiogenic factors (Yoo et al., 2006). The 
expression of MTA1 was strongly induced under 
hypoxic conditions in breast cancer cell lines, and 
MTA1 protein over-expression enhanced the 
transcriptional activity and stability of HIF-1α protein. 
MTA1 protein physically bound to HIF-1α and 
deacetylated it by increasing the expression of HDAC1, 
leading to the stabilization of HIF-1α (Yoo et al., 
2006). These results indicated possible positive cross-
talk between MTA1 and HIF-1α, mediated by HDAC1 
recruitment. 
Moon et al. (2006) found a close connection between 
MTA1-associated metastasis and HIF-1α-induced 
tumor angiogenesis. They showed that MTA1 protein 
increased the transcriptional activity of HIF-1α and a 
target molecule of HIF-1α, vascular endothelial growth 
factor (VEGF). Conditioned medium collected from 
MTA1-transfectants increased angiogenesis in vitro and 
in vivo (Moon et al., 2006). Functional links between 
HIF-1α and MTA1 protein have been demonstrated in 
clinical samples of pancreatic carcinoma. Using 
immunohistochemistry and surgically resected 
pancreatic carcinomas Miyake et al. (2008) examined 
the expression of HIF-1α, HDAC1 and MTA1 proteins 
and suggested that HIF-1α expression, which is 
associated with a poor prognosis in patients with 
pancreatic cancers, might be regulated by 
HDAC1/MTA1 complexes. The contribution of MTA1 
protein to tumor angiogenesis was also demonstrated in 
human breast cancers. Using immunohistochemistry 
Jang et al. (2006) examined MTA1 protein expression 
and intra-tumoral microvessel density (MVD) in 
clinical samples of breast cancer and showed that 
MTA1 protein expression was significantly correlated 
with higher tumor grade and higher tumor MVD. 
The relationship between MTA1 protein expression and 
MVD was also observed in hepatitis B-associated HCC 
(Ryu et al., 2008). In this tumor system hepatitis B 
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virus X protein (Hbx) induces the expression of MTA1 
protein and its HDAC1 complex, which enhances 
hypoxia signaling in HCC (Yoo et al., 2006). This 
suggests that the HDAC1 complex containing MTA1 
protein may be important in stabilizing HIF-1α, and 
thus play a role in angiogenesis and metastasis. 
The relationship between the protein members of 
NuRD complexes, including MTA1 and MTA2 
proteins, and the ataxia teleangiectasia mutated (ATM)- 
and Rad3-related protein (ATR) has been shown by co-
immunoprocipitation of these proteins (Schmidt and 
Schreiber, 1999). ATR is a phosphatidylinositol-
kinase-related kinase that has been implicated in the 
response of human cells to multiple forms of DNA 
damage and may play a role in the DNA replication 
checkpoint. This suggests that MTA proteins may 
contribute to the regulation of DNA checkpoints (Toh 
and Nicolson, 2009). 
4.4 MTA proteins: other possible functions in 
cancer cells 
Other reports have been forthcoming suggesting some 
possible roles of MTA proteins in carcinogenesis and 
cancer progression. The most important of these may
be the relationship of MTA1 protein with c-MYC 
oncoprotein (Figure 2). Using expression profiling, 
Zhang et al. (2005) identified the MTA1 protein as a 
target of the c-MYC protein in primary human cancer 
cells. They showed that c-MYC binds to the genomic 
MTA1 locus and recruits transcriptional co-activators. 
They also found that the MTA1 proteins in NuRD 
complexes were one of the first downstream targets of 
c-MYC function, and this was essential for the 
transformation potential of c-MYC. Indeed, reduction 
of MTA1 expression by a short hairpin RNA blocked 
the ability of c-MYC to transform mammalian cells 
(Zhang et al., 2005). 
Another milestone was the establishment of a 
transgenic mice model that over-expressed MTA1 
protein. Kumar and his collaborators found that the
MTA1-transgenic mice showed inappropriate 
development of mammary glands. These mice also 
developed hyperplastic nodules and mammary tumors 
(Bagheri-Yarmand et al., 2004; Singh and Kumar, 
2007). In this study, the underlying molecular 
mechanisms of MTA1 protein action and its regulation 
were also examined, and the results suggested that 
MTA1 protein dysregulation in mammary epithelium 
and cancer cells triggered down-regulation of the 
progesterone receptor-B isoform and up-regulation of 
the progesterone receptor-A isoform, resulting in the
up-regulation of the progesterone receptor-A target 
genes Bcl-XL and cyclin D1 in mammary glands of 
virgin mice. These authors also found that spontaneous 
B-cell lymphomas were induced in the MTA1-
transgenic mice (Bagheri-Yarmand et al., 2007). 
Recently, Molli et al. (2008) reported that 
MTA1/NuRD complexes negatively regulated BRCA1 
transcription by physically associating with ERE of the 
BRCA1 promoter in an ERα-dependent manner. This 
repressive effect of MTA1 on BRCA1 expression 
resulted in the acquisition of abnormal centrosomes and 
chromosomal instability (Molli et al., 2008). 
The expression of MTA1 and HDAC1 proteins can also 
be increased by the interaction of hepatitis B virus X 
(HBx) protein at the transcriptional level (Yoo et al., 
2008). Since MTA1 and HDAC1/2 proteins are 
physically associated with HIF-1α in vivo in the 
presence of HBx protein, HBx-induced deacetylation 
stabilizes HIF-1α by inhibiting proteosomal 
degradation. These results indicated the existence of 
positive cross-talk between HBx and the MTA1/HDAC 
complex, and it further suggests that such cross-talk 
may play a role in angiogenesis and metastasis of 
HBV-associated hepatocellular carcinomas. 
Direct interactions between MTA1 protein and 
endophilin 3 have also been reported by Aramaki et al. 
(2005). This suggests that MTA1 protein might be 
involved in the regulation of endocytosis mediated by 
endophilin 3. 
An important treatment modality in cancer is the usof 
ionizing radiation. MTA1 protein has been implicated 
in ionizing radiation-induced DNA damage response by 
regulating p53-dependent DNA repair (Li et al., 
2009a). 
5. MTA/MTA genes and proteins as 
new clinical targets 
This review and others (Nicolson et al., 2003; 
Manavathi and Kumar, 2007; Toh and Nicolson, 2009) 
have discussed the available data on the likelyhood that 
MTA proteins have important and critical roles in the 
genesis and progression of a wide variety of cancers. 
MTA1 protein can be thought of as a master co-
regulatory molecule (Manavathi and Kumar, 2007; Toh
and Nicolson, 2009). This clearly suggests the 
possibility that MTA1 protein (or the MTA1 gene or its 
RNA product) could be an excellent molecular target 
for cancer therapy as well as its use in cancer 
diagnosis/prognosis. 
The first studies that suggested the possibility of 
targeting MTA1 RNA were reported by Nawa et al. 
(2000) and Nicolson et al. (2003). Using antisense 
phosphorothioate oligonucleotides against MTA1 
mRNA, these authors found growth inhibitory effects 
and inhibition of invasion of human metastatic breast 
cancer cell lines. 
Different techniques have been used to regulate 
MTA1/MTA1 expression in order to determine the 
effects of MTA1 protein on cellular functions. Using 
RNA interference (RNAi) Qian et al. (2007) inhibited 
MTA1 expression in a human esophageal squamous 
cell carcinoma cell line and demonstrated significant 
inhibition of in vitro invasion and migration properti s 
of the cancer cells (Qian et al., 2005). In a metastasi  
model based on murine melanoma Qian et al. (2007) 
examined the therapeutic use of lowering MTA1  
MTA1 of the MTA (metastasis-associated) gene family and its encoded proteins:  Toh Y, Nicolson GL 





Atlas Genet Cytogenet Oncol Haematol. 2011; 15(3)  312 
protein levels in the melanoma cells and demonstrated 
that down-regulation of MTA1 protein by RNAi 
successfully suppressed growth in vitro and 
experimental metastasis in vivo. Using microRNAs 
against MTA1 Reddy et al. (2009) were able to inhibit 
the expression of MTA1 protein in human breast cancer 
cells, resulting in decreased cell mobility, invasiveness, 
anchorage-dependent growth and tumorigenicity. 
Results such as these suggest a potential role of the 
MTA1 gene as a target for cancer gene therapy. 
Other MTA/MTA genes and proteins may also be 
useful targets. For example, MTA1s may be a useful 
target in the treatment of breast cancer. MTA1s 
functions as a repressor of ERα transcriptional activity 
by binding and sequestering the ERα in the cytoplasm 
(Kumar et al., 2002). MTA1s has a unique C-terminal 
33-amino acid region containing a nuclear receptor-box 
motif that mediates the interaction of MTA1s protein 
with ERα. Singh et al. (2006) showed that the MTA1s 
peptide containing this motif could effectively repss 
the ERα transactivation function, measured by 
estrogen-induced proliferation and anchorage-
independent growth of the human breast cancer cell 
line MCF-7. Using an animal model they also showed 
the effect of MTA1s peptide in blocking tumor 
progression of MCF-7 breast cancer cells that over-
expressed ERα (Singh et al., 2006). 
The use of MTA1 protein as a target of immunotherapy 
has also been considered. MTA1 protein is a promising 
antigen for tumor rejection, because it is over-
expressed in many different tumors and is only 
expressed at lower levels in normal tissues (Toh and 
Nicolson, 2009). In reviewing a model for 
immunotherapy Assudani et al. (2006) proposed using 
a vector that contained disabled infectious single cycle-
herpes simplex virus (DISC-HSV). Their initial studies 
demonstrated the presence of immunogenic MHC class 
I-restricted peptides of MTA1 protein. Next, MTA1 
protein was identified as a SEREX antigen, and hence 
it is likely to be capable of inducing a T-cell response 
in cancer patients (Chen and Han, 2001). 
6. MTA/MTA genes and proteins: 
future directions 
This and previous reviews (Toh and Nicolson, 2003; 
Manavathi and Kumar, 2007; Toh and Nicolson, 2009) 
have focused on the clinical and biological significance 
of the newly emerging gene family named MTA. The 
family of MTA proteins is made up of transcriptional 
co-repressors that function via NuRD complexes 
containing chromatin remodeling and histone 
deacetylating molecules. These actions clearly have a 
role in tumor formation and progression. For example, 
the repression of ERα trans-activation function by 
MTA1 protein through deacetylation of ERE chromatin 
of the ER-responsive genes has been the most 
extensively investigated, and the data clearly 
demonstrated that MTA1 expression results in tumor  
formation in mammary glands and renders breast 
cancer cells phenotypically more aggressive (reviewed 
in Manavathi and Kumar, 2007). 
In addition to chromatin histones, MTA proteins also 
deacetylate non-histone proteins. For example, the 
tumor suppressor p53 protein is deacetylated and 
inactivated by both MTA1 and MTA2 proteins, 
resulting in inhibition of growth arrest and apoptosis. 
HIF-1α is also deacetylated and stabilized by MTA1, 
leading to angiogenesis. Thus, it has been proposed that 
MTA proteins, especially MTA1 protein, represent 
master co-regulatory molecules involved in the 
carcinogenesis and progression of various malignant 
tumors (Manavathi and Kumar, 2007; Toh and 
Nicolson, 2009). Since, it is assumed that these 
properties are important to the survival and progression 
of cancer cells, ultimately this could lead to novel 
clinical applications of MTA genes or MTA proteins as 
new molecular targets for cancer therapy. 
There are other examples of the potential use of MTA 
proteins as therapeutic targets. Inhibition of MTA1 
protein expression or function may enhance the 
chemosensitivity of cancer cells by restoring tumor 
suppressor function of p53, or it may inhibit tumor 
angiogenesis by destabilizing the angiogenesis 
promoting function of HIF-1α. Moreover, MTA 
proteins may cooperate with HDAC inhibitors, which 
are now expected to be the target of a new class of 
anticancer agents (Toh and Nicolson, 2009). 
MTA1 will also be clinically useful for the prognosis or 
prediction of the malignant potentials of various human 
cancers, such as esophageal, gastric and colorectal 
cancers (Toh and Nicolson, 2009). Thus, evaluating the 
expression levels of MTA proteins in individual cases 
of various cancers may provide us with important 
clues. 
Finally, the MTA proteins are clearly present in 
completely normal cells to provide them with certain 
necessary functions. Thus, it will be important to 
understand their physiological functions and underlying 
mechanisms in normal cells. For example, C. elegans 
has MTA1 homologues, egl-27 and egr-1, that functio 
in embryonic patterning and development (Solari et al., 
1999; Chen and Han, 2001), suggesting that MTA1 
protein may have an embryonic developmental 
function. MTA1 protein is also thought to play a cru ial 
role in postnatal testis development and 
spermatogenesis (Li et al., 2007a; Li et al., 2007b), and 
MTA1 protein is a direct stimulator of rhodopsin 
expression (Manavathi et al., 2007a). These are only a 
few of the known physiological functions of MTA1 
protein (Toh and Nicolson, 2009), and it is expected 
that other MTA proteins have important roles in normal 
physiology and development. Thus, determining the 
normal physiological functions of MTA proteins will 
be absolutely necessary in understanding the 
pathological functions of MTA proteins in human 
cancers.  
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